|
| | Publication Year | Title | Author(s) |
| 121 | 15-Jun-2021 | Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M ; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 2 | Feb-2022 | Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. | Lickliter, Jason D; Voskoboynik, Mark; Mileshkin, Linda; Gan, Hui K ; Kichenadasse, Ganessan; Zhang, Kathy; Zhang, Maggie; Tang, Zhiyu; Millward, Michael |
| 3 | 22-Aug-2022 | Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review. | Gunjur, Ashray ; Balasubramanian, Adithya ; Hafeez, Umbreen ; Menon, Siddharth; Cher, Lawrence M ; Parakh, Sagun ; Gan, Hui K |
| 4 | 17-Mar-2015 | Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. | Price, Timothy J; Bruhn, M A; Lee, C K; Hardingham, J E; Townsend, A R; Mann, K P; Simes, J; Weickhardt, A ; Wrin, J W; Wilson, K; Gebski, V; Van Hazel, G; Robinson, B; Cunningham, D; Tebbutt, Niall C |
| 5 | 1-Mar-2006 | Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. | Cher, Lawrence M ; Murone, Carmel ; Lawrentschuk, Nathan; Ramdave, Shanker; Papenfuss, Anthony; Hannah, Anthony; O'Keefe, Graeme J; Sachinidis, John I; Berlangieri, Salvatore U ; Fabinyi, Gavin C ; Scott, Andrew M |
| 6 | 28-Sep-2023 | Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170. | Margalit, Ofer; Harmsen, William S; Shacham-Shmueli, Einat; Voss, Molly M; Boursi, Ben; Wagner, Anna D; Cohen, Romain; Olswold, Curtis L; Saltz, Leonard B; Goldstein, Daniel A; Hurwitz, Herbert; Tebbutt, Niall C ; Kabbinavar, Fairooz F; Adams, Richard A; Chibaudel, Benoist; Grothey, Axel; Yoshino, Takayuki; Zalcberg, John; de Gramont, Aimery; Shi, Qian; Lenz, Heinz-Josef |
| 7 | 2-Dec-2021 | Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. | Reck, M; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Sakai, H; Lingua, A; Reyes, F; Souquet, P-J; De Marchi, P; Martin, C; Pérol, M; Scherpereel, A; Lu, S; Paz-Ares, L; Carbone, D P; Memaj, A; Marimuthu, S; Zhang, X; Tran, P; John, Thomas |
| 8 | 8-Nov-2013 | The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. | Carter, Hannah E; Zannino, Diana; John Simes, R; Schofield, Deborah J; Howard, Kirsten; Zalcberg, John R; Price, Timothy J; Tebbutt, Niall C |
| 9 | May-2017 | Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing. | Doble, Brett; John, Thomas ; Thomas, David; Fellowes, Andrew; Fox, Stephen; Lorgelly, Paula |
| 10 | 16-Mar-2020 | Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. | Hardcastle, Nicholas; Kron, Tomas; Cook, Olivia; Lehmann, Joerg; Mitchell, Paul L R ; Siva, Shankar |
| 11 | 26-Feb-2014 | A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. | Do, Hongdo; Wong, Nicholas C; Murone, Carmel ; John, Thomas ; Solomon, Benjamin J; Mitchell, Paul L R ; Dobrovic, Alexander |
| 12 | 31-May-2016 | Current and evolving methods to visualize biological data in cancer research | Chia, Puey Ling ; Gedye, Craig; Boutros, Paul C; Wheatley-Price, Paul; John, Thomas |
| 13 | 2020 | Current Development of Monoclonal Antibodies in Cancer Therapy. | Parakh, Sagun ; King, Dylan ; Gan, Hui K ; Scott, Andrew M |
| 14 | Sep-2019 | DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it? | Arulananda, Surein; Mitchell, Paul L R ; John, Thomas |
| 15 | Sep-2017 | De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer. | Thai, Alesha; Chia, Puey L; Russell, Prudence A; Do, Hongdo; Dobrovic, Alexander ; Mitchell, Paul L R ; John, Thomas |
| 16 | Jun-2021 | A deep-learning system for the assessment of cardiovascular disease risk via the measurement of retinal-vessel calibre. | Cheung, Carol Y; Xu, Dejiang; Cheng, Ching-Yu; Sabanayagam, Charumathi; Tham, Yih-Chung; Yu, Marco; Rim, Tyler Hyungtaek; Chai, Chew Yian; Gopinath, Bamini; Mitchell, Paul L R ; Poulton, Richie; Moffitt, Terrie E; Caspi, Avshalom; Yam, Jason C; Tham, Clement C; Jonas, Jost B; Wang, Ya Xing; Song, Su Jeong; Burrell, Louise M ; Farouque, Omar ; Li, Ling Jun; Tan, Gavin; Ting, Daniel S W; Hsu, Wynne; Lee, Mong Li; Wong, Tien Y |
| 17 | 2018 | Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. | Parakh, Sagun ; Cebon, Jonathan S ; Klein, Oliver |
| 18 | Nov-2023 | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06. | Barry, Nathaniel; Francis, Roslyn J; Ebert, Martin A; Koh, Eng-Siew; Rowshanfarzad, Pejman; Hassan, Ghulam Mubashar; Kendrick, Jake; Gan, Hui K ; Lee, Sze Ting ; Lau, Eddie ; Moffat, Bradford A; Fitt, Greg ; Moore, Alisha; Thomas, Paul; Pattison, David A; Akhurst, Tim; Alipour, Ramin; Thomas, Elizabeth L; Hsiao, Edward; Schembri, Geoffrey P; Lin, Peter; Ly, Tam; Yap, June; Kirkwood, Ian; Vallat, Wilson; Khan, Shahroz; Krishna, Dayanethee; Ngai, Stanley; Yu, Chris; Beuzeville, Scott; Yeow, Tow C; Bailey, Dale; Cook, Olivia; Whitehead, Angela; Dykyj, Rachael; Rossi, Alana; Grose, Andrew; Scott, Andrew M |
| 19 | 2023 | Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. | Lassman, Andrew B; Pugh, Stephanie L; Wang, Tony J C; Aldape, Kenneth; Gan, Hui K ; Preusser, Matthias; Vogelbaum, Michael A; Sulman, Erik P; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; Macsai, Marian S; Gilbert, Mark R; Bain, Earle E; Blot, Vincent; Ansell, Peter J; Samanta, Suvajit; Kundu, Madan G; Armstrong, Terri S; Wefel, Jeffrey S; Seidel, Clemens; de Vos, Filip Y; Hsu, Sigmund; Cardona, Andrés F; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard A; Gedye, Craig; Bourg, Véronique; Wick, Antje; Curran, Walter J; Mehta, Minesh P |
| 20 | 17-Dec-2022 | Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers. | Halkett, Georgia K B; Breen, Lauren J; Berg, Melissa; Sampson, Rebecca; Sim, Hao-Wen; Gan, Hui K ; Kong, Benjamin Y; Nowak, Anna K; Day, Bryan W; Harrup, Rosemary; James, Melissa; Saran, Frank; Mcfarlane, Brett; Tse, Chris; Koh, Eng-Siew |
